Serum levels of YKL-40 also increased in non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C-induced liver fibrosis [21, 22, 27, 28]. This evidence concerns the gene CHI3L1 and metabolic dysfunction-associated steatotic liver disease.